Abstract
Aims For patients surviving out-of-hospital cardiac arrest (OHCA) with a shockable rhythm, implantable cardioverter defibrillator (ICD) is recommended for non-reversible causes of arrest. We aimed to determine factors associated with implantation of ICD and survival in patients surviving non-AMI OHCA in a nationwide register covering all OHCAs in Denmark. Methods and results We identified 36 950 OHCAs between 2001 and 2012, 1700 of whom were ICD nai?ve, >18 years, of non-AMI cardiac aetiology and surviving until discharge. Six hundred fifty eight patients had ICD implanted during index admission. Association to ICD implantation during index admission was analysed in logistic regression, survival was assessed using Cox regression. Implantable cardioverter defibrillator implantation increased during the study period [odds ratio (OR) 1-year increase: 1.04, 95% confidence intervals (95% CI): 1.00?1.08, P = 0.03]. Non-shockable rhythm and age >70 years were associated with lower odds of ICD implantation (ORnon-shockable: 0.27, 95% CI: 0.19?0.37, P < 0.001, OR70?79 years: 0.71, 95% CI: 0.52?0.98, P = 0.04, OR>80 years: 0.13, 95% CI: 0.07?0.22, P < 0.001). Non-AMI ischaemic heart disease, highest income tertile and chronic heart failure were associated with higher odds (ORIHD: 2.51, 95% CI: 1.77?3.60, P < 0.001, ORhighest income tertile: 1.58, 95% CI: 1.06?2.23, P = 0.02, ORHF: 1.77, 95% CI: 1.35?2.32, P < 0.001). Implantable cardioverter defibrillator implantation was associated with a lower risk of mortality (HR: 0.70, 95% CI: 0.53?0.92, P = 0.01). Conclusion Implantable cardioverter defibrillator implantation rates increased over the study period. CHF, previous IHD and high income were associated with ICD implantation, while older age and non-shockable rhythm was associated with lower odds of ICD implantation. Implantable cardioverter defibrillator implantation was associated with higher survival rates.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | EP - Europace |
| Vol/bind | 20 |
| Udgave nummer | 7 |
| Sider (fra-til) | 1129-1137 |
| ISSN | 1099-5129 |
| DOI | |
| Status | Udgivet - 1. jul. 2018 |
| Udgivet eksternt | Ja |
Bibliografisk note
Funding Information:This work was supported by a grant from the Research Committee at Rigshospitalet to MSc. Winther-Jensen. Dr Lippert reports unrestricted research grants from The Danish foundation TrygFonden and the Laerdal foundation. Dr Steen Hansen has received a research grant from the Danish Heart Foundation and the Laerdal Foundation. Dr Kragholm reports having received grants from The Laerdal Foundation, outside the present study. The Danish Out-of-hospital Cardiac Arrest Registry is supported by TrygFonden. Professor Christensen is supported by TrygFonden, through a non-personal grant to Aalborg University.
Funding Information:
Conflicts of interest: Dr Hassager reports personal lecture fee from Novartis, Orion, TEVA, and ViCare, outside the submitted work. Dr Kjaergaard reports personal lecture fees from Astra Zeneca, Orion Pharma and Bayer, outside the submitted work. Dr Lassen reports personal lecture fees from Astra Zeneca, and Boehringer Ingelheim outside the present study. Dr Kragholm reports having received speaker’s honorarium from Novartis. Professor Køber reports personal lecture fee outside this work from Novartis and Sanofi-Aventis. Professor Torp-Pedersen has received grants and speakers honoraria from Bayer and a grant from Biotronic, outside of the present study. All other authors report no conflicts of interest.
Publisher Copyright:
©The Author(s) 2018.
Finansiering
This work was supported by a grant from the Research Committee at Rigshospitalet to MSc. Winther-Jensen. Dr Lippert reports unrestricted research grants from The Danish foundation TrygFonden and the Laerdal foundation. Dr Steen Hansen has received a research grant from the Danish Heart Foundation and the Laerdal Foundation. Dr Kragholm reports having received grants from The Laerdal Foundation, outside the present study. The Danish Out-of-hospital Cardiac Arrest Registry is supported by TrygFonden. Professor Christensen is supported by TrygFonden, through a non-personal grant to Aalborg University. Conflicts of interest: Dr Hassager reports personal lecture fee from Novartis, Orion, TEVA, and ViCare, outside the submitted work. Dr Kjaergaard reports personal lecture fees from Astra Zeneca, Orion Pharma and Bayer, outside the submitted work. Dr Lassen reports personal lecture fees from Astra Zeneca, and Boehringer Ingelheim outside the present study. Dr Kragholm reports having received speaker’s honorarium from Novartis. Professor Køber reports personal lecture fee outside this work from Novartis and Sanofi-Aventis. Professor Torp-Pedersen has received grants and speakers honoraria from Bayer and a grant from Biotronic, outside of the present study. All other authors report no conflicts of interest.
Fingeraftryk
Dyk ned i forskningsemnerne om 'Association between socioeconomic factors and ICD implantation in a publicly financed health care system: A Danish nationwide study'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver